Patient and physician satisfaction with proton pump inhibitors (PPIs): are there opportunities for improvement?
BACKGROUND
Few studies have explored the satisfaction with proton pump inhibitors (PPIs) for gastroesophageal reflux disease (GERD).


OBJECTIVE
The aim of this study was to assess patient and physician satisfaction with currently prescribed PPIs for patients with GERD.


METHODS
Separate online surveys were completed by 1,002 physicians and 1,013 GERD patients. Physician surveys examined satisfaction, symptom relief, long-term therapy, side-effects, breakthrough symptoms, and use of supplemental medications with PPIs. Patient surveys evaluated PPI regimen, length of therapy, satisfaction with PPI, symptom relief, use of supplemental medications, and perceptions about long-term use and side-effects.


RESULTS
Most respondents were satisfied with PPI therapy, but 35.4% of GERD patients and 34.8% of physicians perceived patients as "somewhat satisfied" to "completely dissatisfied" with PPI therapy. Patients who were highly satisfied were more likely to indicate complete symptom relief (P < 0.001) relative to patients who were less satisfied. However, over 35% of patients on once-daily and 54% on twice-daily PPI indicated that therapy failed to completely relieve symptoms. Patients who were highly satisfied were more likely to recommend medication to patients with the same symptoms (P < 0.001) and less likely to report that the medication is too expensive (P < 0.001), worry about long-term use (P < 0.001), or add OTC medications for supplemental control (P < 0.004).


CONCLUSIONS
Approximately one-third of GERD patients reported persistent symptoms and were dissatisfied with PPI therapy.
Chey
William D
WD
Division of Gastroenterology, University of Michigan Health System, 3912 Taubman Center, Ann Arbor, MI 48109-0362, USA. wchey@umich.edu
Mody
Reema R
RR
Izat
Esin
E
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D005764:Gastroesophageal Reflux / Q000188:drug therapy*; D006801:Humans; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D054328:Proton Pump Inhibitors / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D054328:Proton Pump Inhibitors
Clin Interv Aging. 2007;2(1):85-92
18044079
Aliment Pharmacol Ther. 2004 May 15;19(10):1041-9
15142193
Gastroenterology. 2002 May;122(5):1500-11
11984534
Aliment Pharmacol Ther. 2008 Oct 1;28(7):841-53
18637097
Aliment Pharmacol Ther. 2007 Aug 1;26(3):443-52
17635379
Aliment Pharmacol Ther. 2000 Oct;14(10):1267-72
11012470
Aliment Pharmacol Ther. 2006 Mar 1;23(5):607-16
16480400
Cochrane Database Syst Rev. 2005 Apr 18;(2):CD003245
15846653
Aliment Pharmacol Ther. 2007 Nov 15;26(10):1355-60
17900268
Pharm World Sci. 2005 Dec;27(6):432-5
16341949
Aliment Pharmacol Ther. 2003 Oct 15;18(8):767-76
14535869
Aliment Pharmacol Ther. 2008 Mar 15;27(6):473-82
18194508
Gut. 2006 Oct;55(10):1398-402
16556669
Aliment Pharmacol Ther. 2008 May;27(10):960-70
18315585
J Am Board Fam Pract. 2005 Sep-Oct;18(5):393-400
16148249